US court grants Sanofi-Aventis/Albany's injunction in generic Allegra case
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories' stock lost some of its sheen in early trade on the Bombay Stock Exchange (BSE) on 14 June, after a US district court granted a preliminary injunction against the company's generic version of Sanofi-Aventis' anti-allergic, Allegra D24 (fexofenadine HCl/pseudoephedrine HCl 180mg/240mg extended release tablet).